| You
are here: Home: BCU 1|2003: Gabriel
N Hortobagyi, MD: Select Publications
Select Publications
Use of aromatase inhibitors in the adjuvant setting
Anastrozole alone or in combination with tamoxifen versus
tamoxifen alone for adjuvant treatment of postmenopausal women with
early breast cancer: First results of the ATAC randomised trial.
Lancet 2002;359(9324):2131-9. Abstract
Pharmacokinetics of anastrozole and tamoxifen alone, and
in combination, during adjuvant endocrine therapy for early breast
cancer in postmenopausal women: A sub-protocol of the 'Arimidex
and Tamoxifen Alone or in Combination' (ATAC) trial. Br
J Cancer 2001;85(3):317-24. Abstract
Baum M. The ATAC (Arimidex, Tamoxifen, Alone or in Combination)
adjuvant breast cancer trial in postmenopausal patients: Factors
influencing the success of patient recruitment. Eur J Cancer
2002;38(15):1984. Abstract
Baum M. A vision for the future? Br J Cancer
2001;85 Suppl 2:15-8. Abstract
Bianco AR. ATAC (‘Arimidex’, Tamoxifen, Alone
or in Combination) trial — Anastrozole is superior to tamoxifen
as adjuvant treatment in postmenopausal women with early breast
cancer. Breast Cancer Res Treat 2002; Abstract
632.
Buzdar A. The ATAC ('Arimidex', Tamoxifen, Alone or in
Combination) trial in postmenopausal women with early breast cancer
— Updated efficacy results based on a median follow-up of
47 months. Breast Cancer Res Treat 2002; Abstract
13.
Buzdar AU. New generation aromatase inhibitors —
From the advanced to the adjuvant setting. Breast Cancer
Res Treat 2002;75 Suppl 1:S13-7; discussion S33-5. Abstract
Buzdar AU. Anastrozole (Arimidex) — An aromatase
inhibitor for the adjuvant setting? Br J Cancer 2001;85
Suppl 2:6-10. Abstract
Goss PE. Preliminary data from ongoing adjuvant aromatase
inhibitor trials. Clin Cancer Res 2001;7(12 Suppl):4397s-4401s;
discussion 4411s-4412s. Abstract
Jones SE. Antiaromatase agents: Evolving role in adjuvant
therapy. Clin Breast Cancer 2002;3(1):33-42. Abstract
Mokbel K. The evolving role of aromatase inhibitors in
breast cancer. Int J Clin Oncol 2002;7(5):279-83. Abstract
Ragaz J. Adjuvant trials of aromatase inhibitors: Determining
the future landscape of adjuvant endocrine therapy. J Steroid
Biochem Mol Biol 2001;79(1-5):133-41. Abstract
Sainsbury R. Beneficial side-effect profile of anastrozole
compared with tamoxifen confirmed by additional 7 months of exposure
data: A safety update from the ’Arimidex’, Tamoxifen,
Alone or in Combination (ATAC) trial. Breast Cancer Res
Treat 2002;
Abstract 633.
Wellington K, Faulds DM. Anastrozole in early breast cancer.
Drugs 2002;62(17):2485-92. Abstract
Winer EP et al. American Society of Clinical Oncology technology
assessment on the use of aromatase inhibitors as adjuvant therapy
for women with hormone receptor-positive breast cancer: Status report
2002. J Clin Oncol 2002;20(15):3317-27. Abstract
Adjuvant chemotherapy for patients with node-negative
breast cancer Aapro MS. Adjuvant therapy of primary breast cancer:
A review of key findings from the 7th International Conference,
St. Gallen, February 2001. Oncologist 2001;6(4):376-85.
Abstract
Abrams JS. Adjuvant therapy for breast cancer —
Results from the USA consensus conference. Breast Cancer
2001;8(4):298-304. Abstract
Boyages J et al. Use of the St Gallen classification for
patients with node-negative breast cancer may lead to overuse of
adjuvant chemotherapy. Br J Surg 2002;89(6):789-96. Abstract
Buchholz TA et al. Impact of systemic treatment on local
control for patients with lymph nodenegative breast cancer treated
with breast-conservation therapy. J Clin Oncol 2001;19(8):2240-6.
Abstract
Fisher B et al. Prognosis and treatment of patients with
breast tumors of one centimeter or less and negative axillary lymph
nodes. J Natl Cancer Inst 2001;93(2):112-20. Abstract
Fisher B et al. Findings from recent National Surgical
Adjuvant Breast and Bowel Project adjuvant studies in stage I breast
cancer. J Natl Cancer Inst Monogr 2001;(30):62-6. Abstract
Fisher B et al. Tamoxifen and chemotherapy for axillary
node-negative, estrogen receptor-negative breast cancer: Findings
from National Surgical Adjuvant Breast and Bowel Project B-23.
J Clin Oncol 2001;19(4):931-42. Abstract
Joly F et al. Long-term quality of life in premenopausal
women with node-negative localized breast cancer treated with or
without adjuvant chemotherapy. Br J Cancer 2000;83(5):577-82.
Abstract
Jones SE et al. Adjuvant chemotherapy with doxorubicin
and cyclophosphamide in women with rapidly proliferating node-negative
breast cancer. Clin Breast Cancer 2002;3(2):147-52. Abstract
Morrow M, Krontiras H. Who should not receive chemotherapy?
Data from American databases and trials. J Natl Cancer
Inst Monogr 2001;(30):109-13. Abstract
|
